January | February | March | April | May | June | July | August | September | October | November | December COMPLETED MERGERS AND ACQUISITIONS - December 2010 Company Acquired Acquired By Or Merged With Date Announced Date Completed Value (M) Terms/Details Avid Radiopharmaceuticals Inc. Eli Lilly and Co. 11/9/10 12/22/10 $300 Lilly paid $300M to buy Avid, which could earn $500M more based on a milestones Genzyme Genetics (unit of Genzyme Corp.; GENZ) Laboratory Corp. of America (NYSE:LH) 9/14
Public Companies | Private Companies PUBLIC COMPANIES - December 2010 Company (Symbol) Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (US$M) Access Pharmaceuticals Inc. (OTC BB:ACCP) Registered direct offering 2.3S $6 Anavex Life Sciences Corp. (OTC BB:AVXL) Private placement of units 0.03U $0.1 Bavarian Nordic A/S (Denmark; CSE:BAVA) Private placement of shares 1.05S DKK205 ($36.2) BioSante Pharmaceuticals Inc. (BPAX) Registered direct
January | February | March | April | May | May - 2013 Company Company Type/Product Area Terms/Details Algeta ASA Lumiphore Inc. Global agreement on incorporation of Lumiphore's Lumi4 complexes in Algeta's targeted radiotherapeutics and companion diagnostics Algeta has an option to the exclusive rights to incorporate Lumi4 isophthalamide chelation technology into future targeted radiopharmaceutical therapeutics for cancer AmorChem InflammatorRx Inc. Research collaboration
January | February | March | April | May | June | July | August | September | October | November | December | December - 2009 Biotech Company Pharma Company Type/Product Area Terms/Details Adimab Inc. Pfizer Inc.; an undisclosed company Agreement for Adimab to deliver fully human antibodies against a central nervous system target selected by Pfizer; the new deal with the undisclosed company will focus on an oncology target Both deals involve up-front fees, milestone payments
January | February | March | April | May | June | July | August | September | October | November | December COMPLETED MERGERS AND ACQUISITIONS - December 2009 Company Acquired Acquired By Or Merged With Date Announced Date Completed Value (M) Terms/Details Applied Genomics Inc. Clarient Inc. (CLRT) 12/22/09 12/22/09 $17.6 Clarient acquired Applied Genomics in an all-stock merger involving 7.6M shares Avigen Inc. (AVGN) MediciNova Inc. (MNOV) 6/25/09 12/18/09 $37 MediciNova acquired Avigen for
Public Companies | Private Companies PUBLIC COMPANIES - December 2009 Company (Symbol) Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (US$M) Advaxis Inc. (OTC BB:ADXS) Sale of FY08 net operating tax losses and research tax credits N/A $0.3 Amsterdam Molecular Therapeutics BV (the Netherlands; Euronext:AMT) Private placement of convertible bonds N/A E5 ($7.3) Arrowhead Research Corp. (ARWR) Private placement of units 5U $3.2 AVAX
Commenced Trading COMMENCED TRADING - December 2009 INITIAL OFFERINGS Company Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Gross (M) Movetis (Belgium; Euronext:MOVE) 12/4/09 12/4/09 6.9S E12.25 N/A E85 ($126) COMMENCED TRADING - November 2009 INITIAL OFFERINGS Company Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Gross (M) No initial public offerings commenced in November. COMMENCED TRADING - October 2009 INITIAL
January | February | March | April | May | June | July | August | September | October | November | December | December - 2009 Company Company Type/Product Area Terms/Details Alkermes Inc. (ALKS) Acceleron Pharma Inc. Licensing agreement for a long-acting Fc fusion technology platform Alkermes gains worldwide rights to Medifusion in return for an up-front payment and equity investment in Acceleron, plus future milestones and royalties Allos Therapeutics Inc. (ALTH) Idis
January | February | March | April | May | June | July | August | September | October | November | December | December - 2008 Company Company Type/Product Area Terms/Details AAIPharma Inc. (PK:AAIIQ) Cortria Corp. Agreement granting Cortria the right to use AAIPharma's controlled-release drug delivery technology, ProCR, in conjunction with its TRIA-662 TRIA-662 is Cortria's lead candidate in Phase II development for dyslipidemia Advanced Cell Technology Inc. (PK:ACTC) CHA
January | February | March | April | May | June | July | August | September | October | November | December | December - 2008 Biotech Company Pharma Company Type/Product Area Terms/Details Acura Pharmaceuticals Inc. (ACUR) King Pharmaceuticals Inc. Exercised option to license a fourth immediate-release opioid analgesic product candidate using Acura's Aversion technology, which is designed to deter common methods of prescription drug misuse and abuse King paid Acura an option
January | February | March | April | May | June | July | August | September | October | November | December COMPLETED MERGERS AND ACQUISITIONS - December 2008 Company Acquired Acquired By Or Merged With Date Announced Date Completed Value (M) Terms/Details Nucleonics Inc. Alnylam Pharmaceuticals Inc. (ALNY) 12/8/08 12/8/08 ND Alnylam acquired the intellectual property assets of Nucleonics Omrix Biopharmaceuticals Inc. (OMRI) Johnson & Johnson 11/24/08 12/31/08 $438 J&J acquired Omrix for
Public Companies | Private Companies PUBLIC COMPANIES - December 2008 Company (Symbol) Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (US$M) Aeolus Pharmaceuticals Inc. (OTC BB:AOLS) Private placement of senior convertible notes and warrants ND $0.125 AMDL Inc. (AMEX:ADL) Private placement of 12% senior notes and warrants ND $1.08 Ardea Biosciences Inc. (RDEA) Private placement of common stock and warrants 2.7S and W for 0.68S $30.6
Follow-on Offerings FOLLOW-ON OFFERINGS - October - December 2008 Company Date Filed Date Comm. Shares/Units (M) Price Gross (M) There were no follow-on offerings in October, November and December FOLLOW-ON OFFERINGS - September 2008 Company Date Filed Date Comm. Shares/Units (M) Price Gross (M) Vertex Pharmaceuticals Inc. (VRTX) 9/18 9/18 8.625S $25.50 $219.9 FOLLOW-ON OFFERINGS - August 2008 Company Date Filed Date Comm. Shares/Units (M
Commenced Trading COMMENCED TRADING - July - December 2008 INITIAL OFFERINGS Company Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Gross (M) No initial public offerings commenced in July, August, September, October, November and December COMMENCED TRADING - June 2008 INITIAL OFFERINGS Company Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Gross (M) PCI Biotech Holding ASA (Norway; OSLO:PCIB) 6/11/08 6/11/08 3S NOK20 ($3.9) 5.4
Follow-on Offerings FOLLOW-ON OFFERINGS - December 2007 Company Date Filed Date Comm. Shares/Units (M) Price Gross (M) Anesiva Inc. (ANSV) 12/13/07 12/26/07 12.3S $4.05 $49.8 EpiCept Corp. (EPCT) 10/14/07 12/4/07 3.3S and W for 1.75S $1.50 $4.95 FOLLOW-ON OFFERINGS - November 2007 Company Date Filed Date Comm. Shares/Units (M) Price Gross (M) Arena Pharmaceuticals Inc. (ARNA) 10/22/07 11/2/07 11S $9.91 $109.01 Biopure Corp. (BPUR) 11
January | February | March | April | May | June | July | August | September | October | November | December December - 2007 Company Company Type/Product Area Terms/Details Advanced Viral Research Corp. (ADVR) Cetek Corp. Agreement under which ADVR acquired certain assets, including rights to two new anticancer compounds, as well as high-throughput affinity-based drug screening technology called AFP ADVR will receive rights to a microbial culture library for screening potential
January | February | March | April | May | June | July | August | September | October | November | December December - 2007 Biotech Company Pharma Company Type/Product Area Terms/Details Abeome Corp. Millipore Corp. Exclusive worldwide marketing and distribution agreement for rights to Abeome's stem cell monoclonal antibody Human Embryonic Stem Cell Antigen-1 Abeome received an undisclosed up-front payment and also will receive royalties on sales by Millipore Addex
January | February | March | April | May | June | July | August | September | October | November | December COMPLETED MERGERS AND ACQUISITIONS - December 2010 Company Acquired Acquired By Or Merged With Date Announced Date Completed Value (M) Terms/Details Avid Radiopharmaceuticals Inc. Eli Lilly and Co. 11/9/10 12/22/10 $300 Lilly paid $300M to buy Avid, which could earn $500M more based on a milestones Genzyme Genetics (unit of Genzyme Corp.; GENZ) Laboratory Corp. of America (NYSE:LH) 9/14